Philippe Moreau, MD, on Updates in Multiple Myeloma Presented at ASCO 2021

Philippe Moreau, MD, of the University Hospital of Nantes, who presented data from part 2 of the phase 3 CASSIOPEIA trial (NCT02541383),¹ spoke with CancerNetwork® at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, regarding recent research in the field of multiple myeloma that may have a notable impact on the treatment paradigm. In particular, the phase 1b/2 CARTITUDE-1 trial (NCT03548207), which investigated the use of ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma, had promising results, according to Moreau.²

Transcription:

At ASCO, we have [had] very important trials and very important results, especially for advanced patients. We have heard about the results of the CARTITUDE-1 trial, the updated analysis of the CAR T-cell therapy [cilta-cel from Janssen. The results seem really great in patients who are triple class refractory with a median progression-free survival that was not yet reached. [These were] very encouraging results. [There was] also a data analysis of bispecifics, such as teclistamab and talquetamab [JNJ-64407564] that was also very promising.

Reference

1. Moreau P, Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol 39, 2021 (suppl 15):8004. doi:10.1200/JCO.2021.39.15_suppl.8004

2. Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021;39(suppl 15):8005. doi:10.1200/JCO.2021.39.15_suppl.8005